Neural Oscillation Dysfunction Validation in Parkinson's Disease

Experiment Overview

ID: NOD-PD-001 Status: Proposed Hypothesis: [Neural Oscillation Dysfunction Hypothesis in Parkinson's Disease](/hypotheses/neural-oscillation-dysfunction-parkinsons) Priority: Medium-High

Study Design

Pathway Diagram: Study Phases

Phase 1: Cross-Sectional Characterization

Objective: Characterize oscillatory patterns across PD severity stages

| Parameter | Specification |
|-----------|---------------|
| Sample Size | 150 PD patients (Hoehn-Yahr 1-4), 50 age-matched controls |
| Recording | Scalp EEG (64-channel) + LFP from STN (DBS patients only) |
| Tasks | Resting-state eyes closed, motor task (ubiquitous finger tapping), cognitive task (Stroop) |
| Analysis | Power spectral density, cross-frequency coupling, phase-amplitude coupling |

Primary Endpoints:

• Beta-band (13-30 Hz) power relative to controls
• Beta-gamma coupling strength
• Theta-gamma cross-frequency coupling

Experiment Overview

ID: NOD-PD-001 Status: Proposed Hypothesis: [Neural Oscillation Dysfunction Hypothesis in Parkinson's Disease](/hypotheses/neural-oscillation-dysfunction-parkinsons) Priority: Medium-High

Study Design

Pathway Diagram: Study Phases

Phase 1: Cross-Sectional Characterization

Objective: Characterize oscillatory patterns across PD severity stages

| Parameter | Specification |
|-----------|---------------|
| Sample Size | 150 PD patients (Hoehn-Yahr 1-4), 50 age-matched controls |
| Recording | Scalp EEG (64-channel) + LFP from STN (DBS patients only) |
| Tasks | Resting-state eyes closed, motor task (ubiquitous finger tapping), cognitive task (Stroop) |
| Analysis | Power spectral density, cross-frequency coupling, phase-amplitude coupling |

Primary Endpoints:

• Beta-band (13-30 Hz) power relative to controls
• Beta-gamma coupling strength
• Theta-gamma cross-frequency coupling

• Correlation with UPDRS-III motor scores
• Correlation with MoCA cognitive scores
• Regional distribution of abnormalities

Phase 2: Longitudinal Progression

Objective: Determine if oscillatory biomarkers predict neurodegeneration

| Parameter | Specification |
|-----------|---------------|
| Duration | 3 years, 6-month visits |
| Sample | 100 early-stage PD (Hoehn-Yahr 1-2), 50 controls |
| Biomarkers | EEG, CSF neurofilament light chain, dopamine transporter SPECT |
| Machine Learning | Random forest for progression prediction |

Primary Endpoints:

• Rate of beta power change per year
• Time to motor milestone (Hoehn-Yahr 3)
• Conversion to dementia (MoCA <26)

Phase 3: Intervention Trial

Objective: Test whether oscillation-modulating therapy slows progression

| Parameter | Specification |
|-----------|---------------|
| Design | Randomized, sham-controlled, double-blind |
| Sample | 80 early PD patients (diagnosed <2 years) |
| Intervention | Transcranial alternating current stimulation (tACS) at gamma frequency (40 Hz) vs. sham |
| Duration | 12 months, 5 sessions/week for first month, then maintenance |
| Primary Endpoint | Change in beta power from baseline |
| Secondary Endpoint | UPDRS-III progression rate |

Rationale: Gamma tACS may restore physiological beta-gamma coupling and reduce pathological beta activity[@de2015].

Methodology

EEG Acquisition Protocol

Equipment: 64-channel ActiveTwo system (BioSemi)
Sampling Rate: 2048 Hz
Reference: CMS-DRL ground
Impedance: <5 kΩ
Filtering: 0.1-500 Hz bandpass, 50 Hz notch
Duration: 5 min resting eyes closed, 3 trials

LFP Recording (DBS Patients)

Equipment: Medtronic 3387 leads, externalized during surgery
Contacts: 0-1 (STN), 0-2 (GPi)
Amplification: 0.1-200 Hz bandpass
Duration: 5 min resting, 3 min motor task

Analysis Pipeline

tACS Intervention Protocol

Device: Starstim tCS system (Neuroelectrics) Parameters:

• Frequency: 40 Hz (gamma)
• Intensity: 1.5 mA (peak-to-peak)
• Duration: 20 min/session
• Montage: M1 contralateral to most-affected side

Expected Results

Hypothesis Validation

If the hypothesis is correct[@sanders2020][@brown2003]:

• Phase 1: Significant beta power elevation in PD vs. controls, severity correlation
• Phase 2: Beta power at baseline predicts progression rate
• Phase 3: Gamma tACS reduces beta power and slows UPDRS progression

Alternative Outcomes

• Beta oscillations correlate with severity but do not predict progression → oscillation dysfunction is biomarker, not mechanism
• tACS has no effect on beta power or progression → oscillations are epiphenomenon

Risk Assessment

| Risk | Mitigation |
|------|-------------|
| tACS may induce seizures (rare) | Strict inclusion/exclusion, monitoring |
| Dropout in longitudinal study | Regular follow-up, compensation |
| LFP recording requires DBS surgery | Include non-surgical EEG cohort |

Budget Estimate

| Item | Cost (USD) |
|------|------------|
| Personnel (2 FTE) | $400,000 |
| Equipment | $150,000 |
| Patient compensation | $200,000 |
| Analysis software | $50,000 |
| Total | $800,000 |

Timeline

• Phase 1: Months 1-12 (recruitment + data collection)
• Phase 2: Months 6-42 (overlapping recruitment)
• Phase 3: Months 24-36 (pilot), 36-60 (full trial)
• Analysis: Months 48-60

Cross-References

• [Neural Oscillation Dysfunction Hypothesis](/hypotheses/neural-oscillation-dysfunction-parkinsons)
• [Neural Oscillations Mechanism](/mechanisms/neural-oscillations)
• [Network Oscillation Dysfunction](/mechanisms/network-oscillation-dysfunction)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Deep Brain Stimulation](/treatments/deep-brain-stimulation)
• [tACS (Transcranial Alternating Current Stimulation)](https://pubmed.ncbi.nlm.nih.gov/25751533/)

References